UB Paderborn / Katalog / Suche / in CDI

1 – 15 von 15

Sortiert nach

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

Clinical cancer research, 2021-04, Vol.27 (7), p.1850-1854

2021

Volltextzugriff (PDF)

Whole-genome association study identifies STK39 as a hypertension susceptibility gene

Proceedings of the National Academy of Sciences - PNAS, 2009-01, Vol.106 (1), p.226-231

2009

Volltextzugriff (PDF)

FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

Clinical cancer research, 2021-02, Vol.27 (4), p.922-927

2021

Volltextzugriff (PDF)

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

Clinical cancer research, 2020-08, Vol.26 (16), p.4280-4288

2020

Volltextzugriff (PDF)

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

Clinical cancer research, 2019-06, Vol.25 (11), p.3205-3209

2019

Volltextzugriff (PDF)

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors

Clinical cancer research, 2022-11, Vol.28 (22), p.4843-4848

2022

Volltextzugriff (PDF)

FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs

Clinical cancer research, 2016-09, Vol.22 (18), p.4545-4549

2016

Volltextzugriff (PDF)

FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors

Clinical cancer research, 2023-09, Vol.29 (18), p.3573

2023

Volltextzugriff (PDF)

Considerations for Developing Targeted Therapies in Low‐Frequency Molecular Subsets of a Disease

Clinical pharmacology and therapeutics, 2018-08, Vol.104 (2), p.282-289

2018

Volltextzugriff (PDF)

Characterization of Variants in the Hypertension-Associated Gene STK39

Dorff, Sarah E

2012

Volltextzugriff (PDF)

From the Cover: Whole-genome association study identifies STK39 as a hypertension susceptibility gene

Proceedings of the National Academy of Sciences - PNAS, 2009-01, Vol.106 (1), p.226-231

2009

Volltextzugriff (PDF)

The relationship between adverse childhood experiences, healthcare utilization, cost of care and medical comorbidities

Child abuse & neglect, 2019-04, Vol.90, p.120-126

2019

Volltextzugriff (PDF)

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Clinical cancer research, 2015-06, Vol.21 (12), p.2666-2670

2015

Volltextzugriff (PDF)

The impact of adverse childhood experiences on healthcare utilization in children

Child abuse & neglect, 2021-01, Vol.111, p.104797-104797, Article 104797

2021

Volltextzugriff (PDF)

First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature

European urology oncology, 2022-08, Vol.5 (4), p.377-387

2022

Volltextzugriff (PDF)

1 – 15 von 15

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(14)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(14)
Dissertationen
(1)

Sprache

Englisch
(15)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(10)
Science & Technology
(10)
Life Sciences & Biomedicine
(9)
Oncology
(8)
United States
(5)
Adult
(4)
Drug Approval
(4)
United States Food And Drug Administration
(4)
Female
(3)
Gene Frequency
(3)
Aces
(2)
Adverse Childhood Experiences
(2)
Animals
(2)
Antineoplastic Agents - Therapeutic Use
(2)
Childhood Experiences
(2)
Childhood Factors
(2)
Childhood Trauma
(2)
Clinical Trials As Topic
(2)
Drug Evaluation, Preclinical
(2)
Family Studies
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

Whole-genome association study identifies STK39 as a hypertension susceptibility gene

FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors

FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs

FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors

Considerations for Developing Targeted Therapies in Low‐Frequency Molecular Subsets of a Disease

Characterization of Variants in the Hypertension-Associated Gene STK39

From the Cover: Whole-genome association study identifies STK39 as a hypertension susceptibility gene

The relationship between adverse childhood experiences, healthcare utilization, cost of care and medical comorbidities

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

The impact of adverse childhood experiences on healthcare utilization in children

First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature

Suchergebnisse filtern